Post-streptococcal glomerulonephritis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
{{CMG}} {{AE}} {{MKK}} | {{CMG}} {{AE}} {{MKK}} | ||
==Overview== | |||
==Medical therapy== | |||
*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3]. | |||
*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3]. | |||
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2]. | |||
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2]. | |||
===Disease Name=== | |||
* '''1 Stage 1 - Name of stage''' | |||
** 1.1 '''Specific Organ system involved 1''' | |||
*** 1.1.1 '''Adult''' | |||
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' | |||
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days | |||
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days | |||
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days | |||
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days | |||
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days | |||
Revision as of 15:03, 14 May 2018
Post-streptococcal glomerulonephritis Microchapters |
Differentiating Post-streptococcal glomerulonephritis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Post-streptococcal glomerulonephritis medical therapy On the Web |
American Roentgen Ray Society Images of Post-streptococcal glomerulonephritis medical therapy |
FDA on Post-streptococcal glomerulonephritis medical therapy |
CDC on Post-streptococcal glomerulonephritis medical therapy |
Post-streptococcal glomerulonephritis medical therapy in the news |
Blogs on Post-streptococcal glomerulonephritis medical therapy |
Directions to Hospitals Treating Post-streptococcal glomerulonephritis |
Risk calculators and risk factors for Post-streptococcal glomerulonephritis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Medical therapy
- Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
- Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
- Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Disease Name
- 1 Stage 1 - Name of stage
- 1.1 Specific Organ system involved 1
- 1.1.1 Adult
- Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
- Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
- Preferred regimen (3): drug name 500 mg q12h for 14-21 days
- Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
- Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
- 1.1.1 Adult
- 1.1 Specific Organ system involved 1